New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

Bottom Line

Looking forward, ongoing studies may help answer the question of whether allopurinol (and potentially other urate-lowering therapies) may reduce mortality in patients who are optimally treated to ACR guideline serum urate goals.

Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.

References

1. Coburn BW, Michaud K, Bergman DA, Mikuls TR. Allopurinol dose escalation and mortality among patients with gout: A national propensity-matched cohort study. Arthritis Rheumatol. 2018 Aug;70(8):1298–1307.
2. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015 Jul;74(7):1368–1372.
3. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009 Jul;48(7):804–806.
4. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431–1446.
5. Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58–68.